Switch theme
Sign up to access all valuation multiples
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company’s distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
1967
1.3K+
LTM Revenue $134M
LTM EBITDA $35.5M
$963M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Procter & Gamble Health has a last 12-month revenue of $134M and a last 12-month EBITDA of $35.5M.
In the most recent fiscal year, Procter & Gamble Health achieved revenue of $131M and an EBITDA of $35.0M.
Procter & Gamble Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Procter & Gamble Health valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $143M | $131M | XXX | XXX | XXX |
| Gross Profit | $84.2M | $101M | XXX | XXX | XXX |
| Gross Margin | 59% | 77% | XXX | XXX | XXX |
| EBITDA | $39.8M | $35.0M | XXX | XXX | XXX |
| EBITDA Margin | 28% | 27% | XXX | XXX | XXX |
| Net Profit | $22.4M | $26.7M | XXX | XXX | XXX |
| Net Margin | 16% | 20% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Procter & Gamble Health's stock price is INR 5167 (or $60).
Procter & Gamble Health has current market cap of INR 85.8B (or $996M), and EV of INR 82.9B (or $963M).
See Procter & Gamble Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $963M | $996M | XXX | XXX | XXX | XXX | $1.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Procter & Gamble Health has market cap of $996M and EV of $963M.
Procter & Gamble Health's trades at 7.2x LTM EV/Revenue multiple, and 27.1x LTM EBITDA.
Analysts estimate Procter & Gamble Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Procter & Gamble Health and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $963M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpProcter & Gamble Health's NTM/LTM revenue growth is -100%
Procter & Gamble Health's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $43K for the same period.
Over next 12 months, Procter & Gamble Health's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Procter & Gamble Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Procter & Gamble Health and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -8% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -12% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $43K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 43% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Procter & Gamble Health acquired XXX companies to date.
Last acquisition by Procter & Gamble Health was XXXXXXXX, XXXXX XXXXX XXXXXX . Procter & Gamble Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Procter & Gamble Health founded? | Procter & Gamble Health was founded in 1967. |
| Where is Procter & Gamble Health headquartered? | Procter & Gamble Health is headquartered in India. |
| How many employees does Procter & Gamble Health have? | As of today, Procter & Gamble Health has 1.3K+ employees. |
| Is Procter & Gamble Health publicy listed? | Yes, Procter & Gamble Health is a public company listed on BOM. |
| What is the stock symbol of Procter & Gamble Health? | Procter & Gamble Health trades under 500126 ticker. |
| When did Procter & Gamble Health go public? | Procter & Gamble Health went public in 1992. |
| Who are competitors of Procter & Gamble Health? | Similar companies to Procter & Gamble Health include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of Procter & Gamble Health? | Procter & Gamble Health's current market cap is $996M |
| What is the current revenue of Procter & Gamble Health? | Procter & Gamble Health's last 12-month revenue is $134M. |
| What is the current EBITDA of Procter & Gamble Health? | Procter & Gamble Health's last 12-month EBITDA is $35.5M. |
| What is the current EV/Revenue multiple of Procter & Gamble Health? | Current revenue multiple of Procter & Gamble Health is 7.2x. |
| What is the current EV/EBITDA multiple of Procter & Gamble Health? | Current EBITDA multiple of Procter & Gamble Health is 27.1x. |
| What is the current revenue growth of Procter & Gamble Health? | Procter & Gamble Health revenue growth between 2023 and 2024 was -8%. |
| Is Procter & Gamble Health profitable? | Yes, Procter & Gamble Health is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
